Skip to main content
Article thumbnail
Location of Repository

Antiplatelet activity should be measured routinely: no

By Philip M.W. Bath
Publisher: American Heart Association
Year: 2009
OAI identifier:
Provided by: Nottingham ePrints

Suggested articles


  1. Altered megakaryocyte–platelet–haemostatic-axis in patients with acute stroke. doi
  2. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. doi
  3. (1987). Aspirin and clopidogrel. Efficacy, safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol. doi
  4. (2005). Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res. doi
  5. (1996). Committee. A randomised, blinded, trial of Clopidogrel versus Aspirin doi
  6. (1996). European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. doi
  7. (2009). for the PROGRESS Collaborative Group. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. doi
  8. (2006). New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotensin Aldosterone Syst. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.